These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21890808)

  • 21. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.
    Polcwiartek C; Sneider B; Graff C; Taylor D; Meyer J; Kanters JK; Nielsen J
    Psychopharmacology (Berl); 2015 Sep; 232(18):3297-308. PubMed ID: 26231497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QTc prolongation and haloperidol: just how risky is this drug?
    Howland RH
    Psychosomatics; 2014; 55(6):741-2. PubMed ID: 25497511
    [No Abstract]   [Full Text] [Related]  

  • 23. Antipsychotic medications and cardiac conduction risks.
    Roman M; Farmer SY
    Issues Ment Health Nurs; 2010 Jan; 31(1):68-70. PubMed ID: 19951166
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs.
    Izumi-Nakaseko H; Nakamura Y; Cao X; Wada T; Ando K; Sugiyama A
    Cardiovasc Toxicol; 2017 Jul; 17(3):319-325. PubMed ID: 27738880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulpiride induced torsade de pointes.
    Huang BH; Hsia CP; Chen CY
    Int J Cardiol; 2007 Jun; 118(3):e100-2. PubMed ID: 17408770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Torsade de pointes after ziprasidone overdose with coingestants.
    Alipour A; Cruz R; Lott RS
    J Clin Psychopharmacol; 2010 Feb; 30(1):76-7. PubMed ID: 20075653
    [No Abstract]   [Full Text] [Related]  

  • 28. Torsades de pointes after administration of low-dose aripiprazole.
    Nelson S; Leung JG
    Ann Pharmacother; 2013 Feb; 47(2):e11. PubMed ID: 23362038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haloperidol-induced torsade de pointes.
    O'Brien JM; Rockwood RP; Suh KI
    Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. QT prolongation with migraine medications.
    Evans RW; Atriham AR
    Headache; 2003; 43(7):809-10. PubMed ID: 12890141
    [No Abstract]   [Full Text] [Related]  

  • 31. Improvement in tardive dyskinesia with aripiprazole use.
    Witschy JK; Winter AS
    Can J Psychiatry; 2005 Mar; 50(3):188. PubMed ID: 15830835
    [No Abstract]   [Full Text] [Related]  

  • 32. [QT prolongation and second-generation antipsychotics: overdose and therapeutic dosage].
    Trojak B; Pinoit JM; Disson-Dautriche A; Bonin B; Giusselmann A
    Therapie; 2004; 59(5):558-61. PubMed ID: 15648310
    [No Abstract]   [Full Text] [Related]  

  • 33. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
    Haddad PM; Anderson IM
    Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine.
    Manini AF; Raspberry D; Hoffman RS; Nelson LS
    J Med Toxicol; 2007 Dec; 3(4):178-81. PubMed ID: 18072173
    [No Abstract]   [Full Text] [Related]  

  • 35. Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine.
    Mittal SR
    J Assoc Physicians India; 2014 May; 62(5):426-7. PubMed ID: 25438492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
    Glassman AH
    J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergency department approach to QTc prolongation.
    Pourmand A; Mazer-Amirshahi M; Chistov S; Sabha Y; Vukomanovic D; Almulhim M
    Am J Emerg Med; 2017 Dec; 35(12):1928-1933. PubMed ID: 28855066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.
    Muzyk AJ; Rivelli SK; Jiang W; Heinz H; Rayfield A; Gagliardi JP
    Drug Saf; 2012 Sep; 35(9):725-31. PubMed ID: 22876752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
    Tisdale JE; Rasty S; Padhi ID; Sharma ND; Rosman H
    J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
    Gury C; Canceil O; Iaria P
    Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.